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Abstract
 
Human histocompatibility leukocyte antigen (HLA)-E is a nonclassical major histocompatibil-
ity complex (MHC) class I molecule which presents a restricted set of nonameric peptides, de-
rived mainly from the signal sequence of other MHC class I molecules. It interacts with CD94/
NKG2 receptors expressed on the surface of natural killer (NK) cells and T cell subsets. Here
we demonstrate that HLA-E also presents a peptide derived from the leader sequence of human
heat shock protein 60 (hsp60). This peptide gains access to HLA-E intracellularly, resulting in
up-regulated HLA-E/hsp60 signal peptide cell-surface levels on stressed cells. Notably, HLA-E
molecules in complex with the hsp60 signal peptide are no longer recognized by CD94/
NKG2A inhibitory receptors. Thus, during cellular stress an increased proportion of HLA-E
molecules may bind the nonprotective hsp60 signal peptide, leading to a reduced capacity to
inhibit a major NK cell population. Such stress induced peptide interference would gradually
uncouple CD94/NKG2A inhibitory recognition and provide a mechanism for NK cells to de-
tect stressed cells in a peptide-dependent manner.
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Introduction
 
NK cells play a major role in innate immune responses and
can provide immediate protection against certain types of
infection. They are also involved in the shaping of subse-
quent adaptive immune responses via the secretion of cy-
tokines. NK cells express both activating and inhibitory re-
ceptors, which interact with MHC class I molecules on
target cells (1). The receptors belong to two major groups,
comprising (a) molecules with C-type lectin like folds
(CTLDs) and a type II membrane topology (e.g. CD94/
NKG2; reference 2), and (b) receptors of the Ig-superfam-
ily with a type I membrane orientation (3).
CD94/NKG2 receptors are expressed by a large propor-
tion of NK cells, both in human and mouse, and interact
with the nonclassical MHC class I molecule HLA-E and its
murine homologue Qa-1
 
b
 
, respectively (4, 5). NKG2A
contains an intracellular immunoreceptor tyrosine-based
inhibitory motif (ITIM) mediating inhibitory signals (6),
whereas NKG2C associates with the immunoreceptor ty-
rosine-based activating motif (ITAM) bearing adaptor mol-
ecule DAP-12, and mediates positive signaling (7). CD94/
NKG2A/C receptors have been reported to discriminate
 
between different HLA-E and Qa-1
 
b
 
 binding peptides (8–
11), but the physiological significance of this selectivity
remains unclear.
 
HLA-E is widely expressed in association with 
 
 
 
2
 
-micro-
globulin and peptide on the surface of cells, albeit at low
levels (12). The peptide loading of HLA-E is believed to be
transporter associated with antigen processing (TAP)-
dependent (13), although there are reports of TAP-inde-
pendent presentation (14, 15). In contrast to classical MHC
class I molecules, HLA-E displays a rather limited polymor-
phism, and its peptide binding cleft is primarily occupied
by nonameric peptides derived from the signal sequence of
certain HLA-A, -B, -C, and -G molecules (5). These pep-
tides share a common motif: methionine at position 2, and
leucine or isoleucine at position 9 (16). Analysis of the
crystal structure of HLA-E has provided an elegant expla-
nation for its peptide selectivity (17). Qa-1
 
b
 
 also primarily
presents peptides derived from the signal sequence of some
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mouse MHC class I molecules, with identical anchor resi-
dues at positions 2 and 9 (18, 19). It has, however, recently
been demonstrated that both HLA-E and Qa-1
 
b
 
 can bind a
diverse array of peptides derived from random peptide li-
braries (8, 20). Furthermore, Qa-1
 
b
 
 can present peptides
derived from mouse and bacterial heat shock protein 60
(hsp60),
 
*
 
 and these complexes can be detected by T cells
via their antigen-specific TCR (21).
Hsp60 is present in all living cellular organisms (22, 23).
In eukaryotic cells it serves a vital function as a mitochon-
drial chaperone, and in bacteria as an intracellular protein
involved in the assembly and disassembly of multi-subunit
protein complexes (24). Increased levels of hsp60 are in-
duced in response to a variety of stress stimuli, e.g. temper-
ature increase, nutrient deprivation, exposure to toxic
chemicals, inflammatory responses, and allograft rejection
(22, 25, 26). Hsp60 is believed to play an important role in
the protection of cells from the consequences of these
harmful stimuli. At the same time it may render these cells
more susceptible to attack by hsp60-directed innate and
adaptive immune responses.
Here we demonstrate that HLA-E can present a peptide
derived from the signal sequence of human hsp60
(hsp60sp). This leads to loss of recognition by CD94/
NKG2A inhibitory receptors, suggesting a mechanism by
which CD94/NKG2A
 
 
 
 NK cells can recognize stressed
cells in a peptide-dependent manner.
 
Materials and Methods
 
Cell Culture.
 
K562 (human HLA class I–negative erythroleu-
kemia), and 721.221 (human HLA class I low B-lymphoblastoid
cell) were maintained in RPMI 1640 (Life Technologies) supple-
mented with 10% heat-inactivated FCS, 2 mM 
 
l
 
-glutamine, 100
U/ml penicillin, and 100 
 
 
 
g/ml streptomycin. Two human
CD94/NKG2A
 
 
 
 (but killer Ig-like receptor [KIR]
 
 
 
) cytotoxic
NK cell lines (NKL; provided by Dr. M. Robertson, Indiana
University School of Medicine, Indianapolis, IN), and Nishi (a
gift from Dr. H. Wakiguchi, Department of Pediatrics, Kochi
Medical School, Kochi, Japan) were grown in IMDM supple-
mented with 7% pooled heat-inactivated human AB
 
 
 
 serum,
200 U IL-2/ml (PeproTech), 2 mM 
 
l
 
-glutamine, 100 U/ml pen-
icillin, and 100 
 
 
 
g/ml streptomycin (Life Technologies). Ba/F3
cells cotransfected with CD94 and NKG2A, CD94, DAP-12,
and NKG2C-green fluorescent protein (GFP) or CD94 and
DAP-12 have been described previously (7). HB-120 (pan-HLA
class I–specific hybridoma) was obtained from American Type
Culture Collection, and was cultured in DMEM supplemented with
10% FCS, 2 mM 
 
l
 
-glutamine, sodium pyruvate, HAT, 100 U/ml
penicillin, and 100 
 
 
 
g/ml streptomycin (Life Technologies).
 
Peptides, HLA-E Stabilization, and Cell Culture Stress Assays.
 
Synthetic peptides, purchased from Research Genetics, were dis-
solved in PBS. The peptides used were B7sp (VMAPRTVLL),
hsp60sp (QMRPVSRVL), B7 R5V (VMAPVTVLL), hsp60
V5R (QMRPRSRVL), and P18I10 (RGPGRAFVTI) (all from
 
Research Genetics). Cells and their HLA-E–transfected deriva-
tives were incubated with synthetic peptides (3–300 
 
 
 
M) at 26
 
 
 
C
for 15–20 h in serum-free AIM-V medium (GIBCO BRL) at a
concentration of 1–3 
 
  
 
10
 
6 
 
cells/ml. Cells were then harvested,
washed in PBS, stained with mAbs, and analyzed by flow cytom-
etry. Cells were subjected to stress by allowing them to grow at
increasing cell density. Briefly, cell cultures were set up at the cell
concentration of 0.2 
 
  
 
10
 
6 
 
cells/ml at different time points for a
period of up to 6 d. At the end point, cell concentration and via-
bility were determined by trypan blue exclusion. The expression
of cell-surface HLA class I molecules was assessed by flow cytom-
etry. Cell cultures with viability 
 
 
 
90% and at three different den-
sities were selected as targets for cytotoxic assays.
 
HLA-E Tetramer Production.
 
HLA-E tetrameric complexes
were generated as described previously (5, 27). Briefly, HLA-E
and 
 
 
 
2
 
-microglobulin (
 
 
 
2
 
m) were overexpressed in 
 
Escherichia coli
 
BL21 pLysS, purified from inclusion bodies, solubilized into a 8 M
urea solution, and then refolded by dilution in vitro with syn-
thetic peptides (B7sp, hsp60sp, B7 R5V, or hsp60 V5R; Re-
search Genetics). Complexes of the HLA-E heavy chain, 
 
 
 
2
 
m
and peptide were purified by size exclusion chromatography on a
Superose12 column (Amersham Biosciences), biotinylated with
BirA enzyme (Avidity) according to the instructions of the man-
ufacturer, then quickly frozen and stored at –80
 
 
 
C. Tetrameric
HLA-E complexes were generated by mixing biotinylated
monomers with streptavidin–phycoerythrin (Molecular Probes)
at a 4:1 molar ratio. Similar quality of the different tetramers was
verified by gel-shift assays, as well as by staining a pan-HLA spe-
cific hybridoma (HB-120).
 
Antibodies and Flow Cytometry.
 
mAbs used were: DX22 (anti-
CD94; DNAX), anti-NKG2A (Z199, a gift from Dr. Lorenzo
Moretta, Istituto Nazionale per la Ricerca sul Cancro, Genova,
Italy), CD56 (B159, BD Biosciences), anti-MHC class I mabs
(DX17, DNAX), and W6/32 (American Type Culture Collec-
tion). The 3H5 (anti-MICA) and 3D12 (anti-HLA-E) mAbs
were provided by Drs. T. Spies and D. Geraghty, respectively
(Fred Hutchinson Cancer Center, Seattle, WA). Anti-hsp60
(ML30) was provided by from Dr. J. Ivanyi (University of Lon-
don, London, England). Anti-MICB (7C5) was generated in our
laboratory by immunizing mice with P815 cells stable transfected
with a pCDNA3 expression vector containing an NH
 
2
 
-terminal
CD8 leader peptide followed by a FLAG epitope and the extra-
cellular, transmembrane and cytoplasmic MICB cDNA. Hybrid-
oma 7C5 (anti-MICB) was selected and shown to bind 721.221
and P815 cells transfected with MICB
 
*
 
002 cDNA expression
vectors, whereas untransfected or control transfected cells as well
as MICA
 
*
 
005 transfected cells were negative (unpublished data).
Second-step reagents were FITC- and PE-conjugated goat anti–
mouse IgG (both from Dakopatts). DAK-GO1 was used as nega-
tive control mAbs for triple-color (Dakopatts). Cells were ana-
lyzed on a FACScan™, Becton Dickinson. Immunofluorescence
staining was done using standard protocols. Briefly, K562 cells
transfected with wild-type or mutant full-length hsp60 signal
peptide-GFP were stained with the nuclear stain Hoechst33342
for 30 min at 37
 
 
 
C and the mitochondrial dye tetramethyl-
rhodamine ethyl ester (TMRE) for 15 min at 37
 
 
 
C, followed by
three washing steps. Cells were analyzed using a Nikon Eclipse
E400 universal microscope connected to a Hamamatsu C4742–
98 digital camera. Appropriate filters for immunofluorescence
analysis of labeled cells were used and images were acquired using
Jasc Paint Shop Pro 6.0 and imported into Adobe Photoshop™.
 
Expression Vectors and Generation of Transfected Cells.
 
Synthe-
sized sense and antisense DNA coding for the full-length hsp60
 
*
 
Abbreviations used in this paper:
 
 GFP, green fluorescent protein; hsp60,
heat shock protein 60; hsp60L, hsp60 leader sequence aa 1-26; hsp60sp,
heat shock protein 60 signal peptide QMRPVSRVL; KIR, killer Ig-like
receptor. 
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signal peptide flanked by a 5
 
 
 
Eco RI/3
 
 
 
 BamHI sites (5
 
 
 
-CGGA
ATTCATGCTTCGGTTACCCACAGTCTTTCGCCAGATG
AGACCGGTGTCCAGGGTACTGGCTCCTCATCTCACGG
GCTTATGGATCCGC-3
 
 
 
) were purchased from Interactiva. The
annealed and digested product was ligated into pEGFP-N3 ex-
pression vector (CLONTECH Laboratories, Inc.). The triplet cod-
ing for a Met-residue at position 11 in the hsp60 signal-peptide was
mutated to a triplet coding for a gly-residue using the following
oligonucleotide primer: 5
 
 
 
-CAGTCTTTCGCCAGGGGAGAC
CGGTGTCCAG-3
 
 
 
 using a site-directed mutagenesis kit according
to the manufacturer’s recommendations (QuikChange™; Stratagene)
and verified by sequencing. HLA-E
 
*
 
0101 and HLA-E
 
*
 
01033
cDNA encoding plasmids (pCDNA3) were provided by Drs. M.
Ullbrecht and E. Weiss (Institut fuer Anthropologie und Human-
genetik, Munich, Germany). 721.221 and K562 cells were trans-
fected by electroporation (Gene Pulser; BioRad Laboratories)
according to standard protocols. For transient cotransfection ex-
periments with HLA-E and the chimeric GFP encoding plasmids
we used a ratio of 10:1 (HLA-E:GFP). Transfected cells were se-
lected in complete medium supplemented with 1 mg/ml G418
(BioRad Laboratories). Stable transfected cells were isolated by
flow cytometry (FACScan™) on the basis of their green fluores-
cent properties.
 
NK Cell–mediated Cytotoxicity Assays.
 
NK cell–mediated cy-
totoxicity was measured using a 2 h standard 
 
51
 
Cr radioisotope re-
lease assay. Briefly, target cells were incubated for 15–20 h at
26
 
 
 
C with the various peptides at concentrations ranging from
1–300 
 
 
 
M, and then labeled with 
 
51
 
Cr. Peptides were washed away
before setting up the assays, except in some experiments where
the nonprotective hsp60sp, B7 R5V, and hsp60 V5R was kept
throughout the assay to assure higher levels of HLA-E expression,
as compared with targets incubated with the protective B7sp. In
mAb blocking experiments, cells were preincubated with mouse
serum, or an irrelevant isotype-matched antibody to block Fc-
receptors. Blocking of either target or effector cells with mAbs
was performed at 4
 
 
 
C, and the antibodies were also included dur-
ing the assays.
 
Results
 
Hsp60sp Stabilizes HLA-E Cell Surface Expression.
 
To
identify peptides derived from human hsp60 with a poten-
tial to bind HLA-E, we searched the full length amino acid
sequence of hsp60 for peptides displaying the HLA-E per-
missive motif (methionine at position 2 followed by either
a leucine or isoleucine at position 9 at the COOH termi-
nus). Among totally four such peptides (Fig. 1 and Table I),
one was found within the hsp60 leader sequence (i.e.,
hsp60sp, QMRPVSRVL; Fig. 1 and Table I). In addition,
hsp60sp not only bears a methionine at position 2 and a
 
leucine at position 9, but also shares amino acids at position
4 and 8 in common with some peptides known to effi-
ciently bind to HLA-E. Thus, four out of the nine amino
acids in hsp60sp are shared with some peptides found in
HLA class I leader sequences (e.g. HLA-A
 
*
 
0201, and
-A
 
*
 
3401, Table I). This homology suggested that hsp60sp
may bind to HLA-E.
Studies on peptide and HLA-E interactions have demon-
strated that the presence of an HLA-E binding peptide, ei-
ther provided in a transfected cDNA expression plasmid, or
by exogenous addition of synthetic peptides, is sufficient to
stabilize and up-regulate HLA-E cell surface expression to
levels detectable by flow cytometry (5, 28, 29). To test
whether the hsp60-derived peptides were able to bind
HLA-E, we stabilized HLA-E cell surface expression with
the different synthetic peptides, by overnight incubation at
26
 
 
 
C. For this purpose we used MHC class I–deficient cell
lines such as 721.221 (which lack HLA-A, -B, -C, and -G,
but express HLA-E and -F intracellularly), as well as K562
cells transfected with HLA-E
 
*
 
01033 (K562-E
 
*
 
01033) or
HLA-E
 
*
 
0101. The 721.221 cells and HLA-E transfected,
but not untransfected, K562 cells express low levels of
HLA-E at the cell surface during normal cell growth. These
base levels of HLA-E expression suggest the presence of
minute amounts of intracellular peptides, enough to stabi-
lize nascent HLA-E molecules. As shown in Fig. 2, using
hsp60sp, a substantial increase in HLA-E expression was
observed in both HLA-E
 
*
 
01033 and HLA-E
 
*
 
0101 trans-
fected K562 cells. The levels of HLA-E expression after
loading with hsp60sp were comparable to the levels of cells
loaded with a peptide derived from the leader sequence of
HLA-B
 
*
 
0701 (B7sp, VMAPRTVLL; Fig. 2). However, at
37
 
 
 
C the HLA-E/hsp60sp complexes dissociated faster than
the HLA-E/B7sp, reaching base levels after 
 
 
 
5 h (data not
depicted). In addition to hsp60sp, the hsp60.4 peptide
(GMKFDRGYI) was also capable of stabilizing HLA-E
molecules on transfected K562 cells as well as on 721.221
cells (data not depicted). This peptide has previously been
shown to also bind to mouse Qa-1
 
b
 
 molecules (21). HLA-E
stabilization was not observed with the other two hsp60-
derived peptides (hsp60.2 and hsp60.3; Table I), possibly
due to poor solubility in the assay medium.
 
Hsp60 Signal Peptide Gains Access to HLA-E Intracellularly
and HLA-E/hsp60sp Levels Are Up-regulated during Cellular
Stress.
 
Hsp60 is a mitochondrial matrix protein, which is
encoded within the genomic DNA (23, 30). It is synthe-
sized as a precursor protein with an NH
 
2
 
-terminal mito-
Figure 1. The protein sequence of hu-
man hsp60. The mitochondrial targeting
signal is shown in gray. Boxed are the four
peptide sequences displaying a methionine
followed by leucine or isoleucine seven
amino acids COOH-terminally, two im-
portant residues for binding to HLA-E
pockets. Hsp60sp corresponds to residues
10–18 in the sequence (QMRPVSRVL). 
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chondrial targeting sequence consisting of 26 amino acids
(i.e., hsp60L, see Fig. 1). Biochemical studies have estab-
lished that cleavage of the hsp60L requires import of the
precursor protein into the mitochondrial matrix, and that
this cleavage is unlikely to occur in the cytosol, as no mito-
chondrial import of hsp60 is observed in the absence of the
hsp60L (31). The final destination for the hsp60L after its
cleavage is unknown. Upon stress, hsp60 is regulated by in-
creased transcription as well as by posttranscriptional events
affecting its intracellular levels and distribution (32–35). In
an effort to follow the localization of the hsp60L, and par-
ticularly whether the hsp60sp can gain access to HLA-E
molecules, we established a system based on K562 cells
transfected with chimeric constructs containing either the
wild-type hsp60L, or a mutated variant in which the me-
thionine at position 11 was substituted by a glycine. This
methionine corresponds to position 2 in hsp60sp nonamer,
and is required for stable binding to HLA-E. The wild-type
and mutated hsp60L were grafted in frame onto the NH
 
2
 
terminus of GFP to ensure that, upon transfection, green
fluorescent cells also translate each of the individual hsp60
leader sequences. After transfection, we observed that GFP
localized inside the mitochondria in the two hsp60L-GFP
transfected cell lines (Fig. 3), indicating that the substitution
of methionine at position 11 did not alter the transport into
the mitochondria. GFP showed no obvious subcellular lo-
calization when the GFP gene was transfected alone (un-
published data).
Previously, Imani and Soloski have demonstrated that
cell surface levels of mouse Qa-1
 
b
 
 molecules are substan-
tially up-regulated during cellular stress (36). Based on the
homology between Qa-1
 
b
 
 and HLA-E, both in terms of
sequence, biological function, and peptide binding specific-
ity, we set up experiments to test whether the nonameric
peptide located inside the mitochondrial targeting sequence
of hsp60 may ultimately gain access to HLA-E, particularly
under conditions of cellular stress. To this end we cotrans-
fected K562 cells with an HLA-E
 
*
 
01033-encoding plasmid
together with either the wild-type hsp60L–GFP construct
or with its mutated variant. We then monitored HLA-E
cell surface expression of these transfectants as the cultures
were subjected to stress by means of growth at increasing
cellular density. Cells transfected with the wild-type
hsp60L–GFP construct consistently expressed higher levels
of HLA-E than cells cotransfected with the mutant con-
struct (Fig. 4 a). It should be noted that this difference de-
pended on the growth conditions; at day 1, the difference
in HLA-E cell surface levels between cells expressing wild-
type and mutated hsp60sp was marginal, while it was sub-
stantial at day 5. We also observed a certain increase of
HLA-E levels in the cells transfected with the mutated
hsp60L–GFP construct when grown under stress versus
normal conditions (Fig. 4 a, day 1 vs. day 5). This could be
due either to a residual capacity of the mutated peptide to
bind HLA-E, or by an access of endogenously derived
hsp60 peptides to HLA-E. Consistent with the latter possi-
bility, we observed increased HLA-E levels as a conse-
quence of culture-induced stress also in K562 cells that had
been transfected with the HLA-E gene alone (Fig. 4 b, bot-
tom panel), whereas untransfected K562 cells remained
HLA-E negative (Fig. 4 b, top panel). However, at this
point we cannot exclude an influence by other HLA-E
binding peptides, nor posttranscriptional, but peptide inde-
pendent, regulation of HLA-E in stressed cells. Note that
the K562-E
 
*
 
01033 cell line and the cotransfected cell lines
presented in Fig. 4 a were generated and selected indepen-
dently, which may account for the higher HLA-E back-
 
Table I.
 
Peptide Sequence Comparisons between HLA Class I 
Molecules and hsp60
 
Protein (Residues)
Peptide
sequence
Signal peptide (SP)
Mature protein (P)
HLA-A*0201 (3–11)
 
VMAPRTLVL
 
SP
HLA-A*0301 (3–11)
 
VMAPRTLLL
 
SP
HLA-A*3401 (3–11)
 
IMAPRTLVL
 
SP
HLA-B*0701 (3–11)
 
VMAPRTVLL
 
SP
HLA-Cw*0102 (3–11)
 
VMAPRTLIL
 
SP
HLA-G*0101 (3–11)
 
VMAPRTLFL
 
SP
hsp60sp (10–18)
 
Q
 
M
 
R
 
P
 
VSR
 
VL
 
SP
hsp60.2 (39–47)
 
L
 
M
 
LQGVD
 
LL
 
P
hsp60.3 (144–152)
 
VM
 
LAVDAVI P
hsp60.4 (216–224) GMKFDRGYI P
Figure 2. Stabilization of HLA-E by hsp60sp and B7sp on K562 cells
transfected either with HLA-E*0101 or HLA-E*01033. Cell surface ex-
pression of HLA-E*0101 (top panel) and HLA-E*01033 (bottom panel)
after overnight incubation at 26 C with 300  M of either hsp60sp (left
panel, bold line) or B7sp (right panels, bold line). The dashed line repre-
sents HLA-E expression after incubation with 300  M of a control pep-
tide (P18I10). Cells were stained with anti-MHC class I mAb DX17,
followed by RPE-conjugated goat anti–mouse IgG. The HLA-E ex-
pression was confirmed by staining with the anti–HLA-E mAb 3D12.
Staining with isotype-matched control antibody is shown as shaded gray.
1 representative experiment out of more than 10 is shown.1407 Michaëlsson et al.
ground level observed at day 1. Therefore, the absolute
levels of HLA-E should not be directly compared between
Fig. 4, a and b.
Our interpretation of the transfectant studies is, that the
stress response results in an increased accessibility of mito-
chondrial hsp60sp to HLA-E intracellularly, eventually
causing up-regulated HLA-E/hsp60sp cell surface levels.
This should at least in part be due to posttranscriptional
control of hsp60sp during the stress response, as both the
hsp60L–GFP and HLA-E constructs used were under con-
trol of the same CMV promoter, and the GFP expression
level did not change with increased cell density (Fig. 4 a).
HLA-E–mediated Presentation of hsp60sp Abrogates Recogni-
tion by CD94/NKG2A and CD94/NKG2C Receptors.
The inhibitory lectin-like receptor heterodimer CD94/
NKG2A is present on  50% of all NK cells in the periph-
eral blood both in humans and mice. This HLA-E–specific
receptor mediates a negative signal upon binding to HLA-E
presenting various protective HLA class I signal peptides,
which results in the inactivation of NK cell effector func-
tions. In a similar fashion, Qa-1b in complex with a permis-
sive MHC class I leader peptide is efficiently recognized by
murine CD94/NKG2A receptors, suggesting evolutionary
conservation in humans and mice at both receptor and
ligand levels.
To characterize possible NK cell receptors that interact
with HLA-E in complex with hsp60sp or MHC class I sig-
nal peptides, we analyzed whether MHC tetrameric com-
plexes could bind CD94/NKG2 receptors expressed on
transfectants and NK cells. Recombinant soluble HLA-E
molecules were refolded in vitro in the presence of human
 2-microglobulin and B7sp (VMAPRTVLL) or hsp60sp
(QMRPVSRVL). The refolded MHC complexes were
used to create tetrameric HLA-E molecules, which enable
analysis of HLA-E binding receptors. Both peptides per-
mitted an effective refolding of HLA-E in vitro and were
effectively biotinylated as analyzed by gel-shift assays (un-
published data). As expected, HLA-E/B7sp tetramers effi-
ciently bound to mouse Ba/F3 pro-B cells cotransfected
with CD94 and NKG2A or CD94, NKG2C, and DAP12
(Fig. 5, a and b). This result was confirmed by staining NK
cell lines that express the inhibitory receptor CD94/
NKG2A (Fig. 5 c), or freshly isolated NK cells expressing
predominantly the CD94/NKG2A receptor (unpublished
data). In contrast, the HLA-E/hsp60sp tetramers failed to
bind Ba/F3 pro-B cells cotransfected with either CD94/
NKG2A or CD94/NKG2C/DAP12, and all NK cells ex-
amined (Fig. 5, a–c). However, both HLA-E/B7sp and
HLA-E/hsp60sp bound to a similar extent to a control B
cell hybridoma, specific for HLA class I molecules (Fig. 5
d). Thus, although hsp60sp can efficiently gain access to
HLA-E physiologically, this complex is no longer recog-
nized by the CD94/NKG2A and CD94/NKG2C recep-
tors, demonstrating that they are peptide selective.
HLA-E/hsp60sp Fails to Inhibit CD94/NKG2A  NK
Cells in Cytotoxic Assays; Critical Role for Position 5 in the
Peptide. To address the functional significance of in-
creased HLA-E/hsp60sp cell surface levels, we investigated
whether cells expressing these MHC complexes were pro-
tected from killing by CD94/NKG2A  NK cells. K562-
E*01033 cells, incubated overnight at 26 C with either
hsp60sp or B7sp peptides, were tested as targets in 2 h
chromium release assays with the CD94/NKG2A  NK
cell lines Nishi and NKL as effectors. A clear protection
from killing was observed when incubating the otherwise
susceptible K562-E*01033 cells with B7sp, whereas incu-
Figure 3. Hsp60 signal peptide targets GFP into mitochondria and the methionine residue at position 11 is not crucial for mitochondrial translocation.
K562 cells were transfected with either a chimeric construct consisting of the wild-type full-length hsp60 signal peptide (residues 1–26) directly upstream
and in frame of GFP (top panel, green), or a mutated variant of the full-length hsp60 signal peptide where the methionine at position 11 was replaced
with a glycine (bottom panel, green). Both constructs target GFP into mitochondria. Cells were counter stained with the mitochondrial probe TMRE
(bright red) and the nuclear stain Hoechst 33342 (blue). An overlay of all colors is shown to the right.1408 Stress-induced Peptides Interfere with CD94/NKG2A Recognition of HLA-E
bation with hsp60sp did not result in any significant protec-
tion (Fig. 6 a). As mentioned above, hsp60sp and B7sp
have different dissociation rates from HLA-E, which could
account for the difference in target susceptibility. There-
fore, the HLA-E surface expression was monitored before
and after the cytotoxic assays, to assure comparable levels of
HLA-E on the targets throughout the assays.
To pinpoint the residues responsible for the loss of HLA-E
recognition by CD94/NKG2A, we introduced mutations
in the B7sp and hsp60sp. It has previously been demon-
strated that a change at p5R in the Qa-1b binding peptide
Qdm abrogated recognition by CD94/NKG2A in the
Figure 4. Up-regulation of HLA-E by
overexpression of the full-length hsp60 signal
peptide is enhanced by cellular stress. HLA-E
surface expression was monitored on cells
growing at increasing densities. Cells were
collected and analyzed for HLA-E expression
between day 1 and day 5 (as indicated on the
top of the histograms). The numbers in the
top right corner of each histogram indicate
cell density (cells/ml) and percent viability at
the time of analysis, respectively. The num-
bers in the bottom right corner of each histo-
gram in panel a indicate the MFI of HLA-E
expression (top, black) and the MFI of GFP
(bottom, gray). The numbers in the lower
right corner of each histogram in b indicate
the MFI of HLA-E expression. All cells were
stained with an HLA specific antibody
(DX17, dashed line) or with control Ig (gray
histogram), followed by RPE-conjugated
goat anti–mouse IgG. (a) K562 cells cotrans-
fected with HLA-E*01033 and the full-
length (residues 1–26) wild-type hsp60 signal
peptide-GFP construct (wild-type hsp60L,
top panel) or mutant hsp60 signal peptide-
GFP (mutated hsp60L, bottom panel), cul-
tured at increasing cell density. A gate was
set on GFP positive cells and 10 000 events
were acquired within this gate. (b) K562
cells (top panel) and K562 transfected with
HLA-E*01033 (K562 E*01033, bottom
panel) cultured at increasing cell density. Note
that the K562-E*01033 cell line in b and the
cotransfected cell lines presented in panel a
were generated and selected independently,
which may account for the higher HLA-E
background level observed at day 1. There-
fore the absolute levels of HLA-E should not
be directly compared between Fig. 4, a and b.
Figure 5. Binding of soluble HLA-E tetrameric molecules to CD94/
NKG2 receptors. (a) Ba/F3 cells transfected with CD94 and NKG2A
were incubated with HLA-E/B7sp tetramers- (bold line), HLA-E/
hsp60sp-tetramers (thin line), or control H-2Db/gp33-tetramers (dashed
line). (b) Ba/F3 cells transfected with CD94, NKG2C, and DAP-12 were
incubated with HLA-E/B7sp-tetramers (bold line), HLA-E/hsp60sp-tet-
ramers (thin line), or control H-2Db/gp33-tetramers (dashed line). (c)
The NK cell line NKL was incubated with HLA-E/B7sp-tetramers (bold
line), HLA-E/hsp60sp-tetramers (thin line), or control H-2Db/gp33-tet-
ramers (dashed line). (d) HB-120 B cell hybridoma (anti-MHC class I)
was incubated with HLA-E/B7sp-tetramers (bold line), HLA-E/hsp60sp-
tetramers (thin line), or control H-2Db/gp33-tetramers (dashed line). All
incubations were done at 4 C for 45 min in PBS supplemented with 1%
FCS. HLA-E/hsp60sp-tetramers failed to bind both CD94/NKG2A 
and CD94/NKG2C  cells over a range of HLA-E/hsp60sp-tetramer
concentrations (not shown). This is one representative experiment of
more than five.1409 Michaëlsson et al.
mouse (8). We therefore chose to mutate position 5
in both peptides, generating the peptides B7 R5V
(VMAPVTVLL) and hsp60 V5R (QMRPRSRVL). The
ability of these peptides to protect K562-E*01033 cells was
tested in cytotoxic assays, as described above. K562-
E*01033 cells incubated at 26 C with B7 R5V expressed
high levels of HLA-E (Fig. 6 c), yet they were efficiently
killed by CD94/NKG2A  NK cells (Fig. 6 b). This muta-
tion is therefore sufficient to abrogate the protective capac-
ity of B7sp. However, the V5R mutation introduced in
hsp60sp was not sufficient to restore protection from killing
using the same effector cells (Fig. 6 b).
Gays et al. recently reported that the hsp60.4 peptide
(GMKFDRGYI) could bind to Qa-1b, but did not induce
protection from CD94/NKG2A  NK cells. However, this
peptide failed to compete with the protective Qdm-pep-
tide for binding to Qa-1b, even when mixed in 100,000-
fold excess with 1 nM Qdm (37). In contrast, we found
that hsp60sp could interfere with HLA-E–mediated pro-
tection by competing with MHC class I signal peptides.
K562-E*01033 cells were incubated with 0.1  M B7sp to-
gether with increasing concentrations of competing pep-
tides and tested in cytotoxic assays. Cells incubated with
0.1  M B7sp and a control peptide remained protected
from killing at all concentrations tested, whereas cells incu-
bated with 0.1  M B7sp and hsp60sp became more suscep-
tible to killing with increasing concentrations of hsp60sp
(Fig. 6 d). The B7 R5V peptide was an even stronger com-
petitor than hsp60sp (Fig. 6 d). In line with the results on
Qa-1b peptide binding competition as reported by Gays et
Figure 6. Hsp60sp fails to protect
K562-E*01033 cells from killing by
NK cells. K562-E*01033 cells were
incubated with the different peptides
at 26 C for 15–20 h, and then tested
in 2h 51Cr release assays. To ensure
that the levels of HLA-E presenting
a protective peptide, and not the
HLA-E levels as such, provided the
protective capacity we kept the non-
protective peptides, but omitted the
B7sp, during the killing assays. (a)
Killing of K562-E*01033 cells by
NKL (left) or Nishi (right) after in-
cubation with 300  M P18I10 con-
trol peptide, 300  M hsp60sp, or 30
 M B7sp. 50  M of P18I10 control
peptide and hsp60sp was also in-
cluded during the assays. Data from
an E:T ratio of 30:1 is shown. The
figure represents the mean of at least
three experiments. Error bars indi-
cate standard error of the mean. (b)
Killing of K562-E*01033 cells by
NKL (left panel) or Nishi (right
panel) incubated over night with 30
 M B7sp, 300  M P18I10 (pCtrl),
300  M B7 R5V, 300  M hsp60sp,
or 300  M hsp60 V5R. 50  M of
all peptides, except B7sp, were in-
cluded during the assay. Peptide
concentrations were chosen accord-
ing to (c). The figure represents the
mean of at least three experiments.
Error bars indicate standard error of
the mean. (c) HLA-E cell surface ex-
pression by K562-E*01033 after the
assay. A cold target preparation was
prepared in parallel as in a and b, and
was stained with DX17 mAb (anti-
HLA class I), followed by RPE-con-
jugated goat anti–mouse IgG after
the 2-h assay. One representative
example out of more than five is
shown. Note that, as in a and b, 50
 M of all peptides, except for B7sp,
was present during the time of the
assay, explaining the lower HLA-E expression with B7sp compared with Hsp60sp, Hsp60 V5R, and B7 R5V. (d) Killing of K562-E*01033 cells by Nishi
after incubation for 30 min at room temperature with 0.1  M B7sp and increasing amounts of competing peptides (hsp60sp, hsp60.4, B7 R5V, and
P18I10). All the peptides were kept throughout the assay.1410 Stress-induced Peptides Interfere with CD94/NKG2A Recognition of HLA-E
al. (37), hsp60.4 was not able to compete with B7sp for
binding to HLA-E (Fig. 6 d).
We also investigated whether the stress-induced HLA-E
cell surface up-regulation observed in K562-E*01033 cells
resulted in protection from NK cell–mediated lysis. K562-
E*01033 cells grown at different densities were tested as
targets in a 2 h chromium release assay with NKL and
Nishi as effector cells. In spite of increased HLA-E levels,
the killing increased rather than decreased, indicating that
the HLA-E molecules induced on these cells were not pro-
tective. All target cells had a viability  90%, as measured
by Annexin V staining and trypan blue (unpublished data).
Moreover, and importantly, the cells grown at high density
could be rescued from killing by addition of B7sp peptide
(Fig. 7 b). This demonstrates that the increased killing was
not terminally decided by the cell culture conditions, and
that the HLA-E levels were sufficient for protection pro-
vided that an appropriate peptide was present. We con-
clude that HLA-E expression induced by stress is not suffi-
cient to protect from NK cell–mediated killing. It should
be noted that although K562 constitutively express MIC-A
and MIC-B, ligands for the activating receptor NKG2D,
these are not further up-regulated by the cellular stress im-
posed in these assays (unpublished data). Therefore, it is
unlikely that the increased killing after cellular stress ob-
served in some of our experiments is due to an increased
expression of MIC-A or MIC-B. We cannot however ex-
clude that up-regulation of other activating ligands, e.g.
ULBP’s (38), are responsible for the increase in killing.
Discussion
Our experiments using synthetic peptides demonstrate
that HLA-E is capable of binding a peptide derived from
the signal sequence of hsp60, and that such complexes can-
not efficiently be recognized by inhibitory CD94/NKG2A
receptors. This was shown by lack of binding of HLA-E/
hsp60sp tetramers to CD94/NKG2A expressing cells and
by NK cell–mediated killing of cells expressing such HLA-
E/peptide complexes. Furthermore, our studies based on
transfected cells suggest that hsp60sp can gain access to
HLA-E molecules in vivo, particularly during conditions of
cellular stress. We propose that the proportion of HLA-E
in complex with this peptide is increased during stress,
leading to a gradual shift in the HLA-E peptide repertoire
from NK cell protective to nonprotective complexes. Ac-
cording to this model, NK cells can detect stressed cells
during infectious and inflammatory responses, through sur-
veillance of HLA-E/peptide complexes in a peptide selec-
tive manner. This could be of particular importance for the
subset of NK cells uniformly expressing CD94/NKG2A as
Figure 7. Increased HLA-E cell surface
levels on K562-E*01033 after cellular stress
does not protect from NK cell mediated
killing. (a) Killing of K562-E*01033 cells
(grown at increasing cell densities as in Fig.
4 b) by NKL in a 2-h 51Cr release assay. (b)
Same experimental setting as above, in the
presence of 100  M B7sp. Closed circles,
high density; open squares, medium density;
closed triangles, low density. (c) HLA-E ex-
pression on the K562-E*l01033 cells after
culture at increasing cell density.1411 Michaëlsson et al.
their main inhibitory receptor, and also for the subset of ac-
tivated T cells that expresses this receptor.
It has previously been discussed whether missing self-
recognition could be based on peptide-specific recogni-
tion, in the sense that normal self peptides in complex with
MHC class I would be permissive for binding of inhibitory
receptors, while viral and other nonself peptides would be
nonpermissive. There is good evidence that some receptors
are strongly influenced by the bound peptide. This applies
to immunoglobulin-like (39–43) as well C-type lectin-like
receptors, including CD94/NKG2A (8–11, 44, 45). How-
ever, the protective capacity does not correlate with the
origin of the peptide, i.e., whether it represents self versus
nonself, or healthy versus sick. The balance between differ-
ent HLA-E complexes may, however, represent a situation
where cells can signal “normal” versus “abnormal” via
peptides competing for MHC dependent presentation.
The HLA-E–mediated protection would thus not only rely
on whether sufficient permissive signal peptides (mainly
from various MHC class I molecules) are produced, but
also on how these are balanced by nonpermissive, stress-
induced peptides. Although KIR recognition of MHC
class I can be influenced by the bound peptides, a mecha-
nism based on peptide selective surveillance of stressed cells
may be primarily associated with the CD94/NKG2 recep-
tors, as these are specifically designed to recognize the oli-
gomorphic HLA-E molecules in complex with a restricted
set of protective peptides. The KIRs, on the other hand,
have primarily evolved to recognize a highly diverse reper-
toire of polymorphic HLA-A, -B, and -C molecules. A
similar surveillance mechanism of stressed cells, if operating
via KIRs, would require the presence of a vast array of
stress-induced peptides capable of being loaded onto each
HLA class I allele.
A first question on such stress-induced peptide interfer-
ence (SPI) with inhibitory recognition relates to the struc-
tural aspects of different HLA-E peptide complexes. The
crystal structure of HLA-E/B7sp reveals that five peptide
residues lie within well-defined pockets of the HLA-E
molecule (17), constraining the conformation of the pep-
tide throughout the binding groove. Comparison between
hsp60sp and MHC class I signal peptide sequences (Table I)
reveals differences at five positions: p1, p3, p5, p6, and p7.
Of these, p3, p6, and p7 are buried in pockets D, C and E,
respectively, while p1 and p5 are exposed to the surface.
Based on the HLA-E/B7sp structure, O’Callaghan et al.
proposed that p5R in B7sp acts as an HLA-E contact resi-
due for an HLA-E binding receptor (17). Indeed, a change
in B7sp from arginine to valine (corresponding residue in
the hsp60sp) at position 5 was sufficient to completely ab-
rogate HLA-E–mediated protection from killing by
CD94/NKG2A expressing NK cells. However, the recip-
rocal change in hsp60sp (valine to arginine at p5) was not
sufficient to gain protection, suggesting that additional
amino acids in this peptide are important. This has drawn
our attention to the arginines at positions 3 and 7, which
appear difficult to fit in the shallow and hydrophobic D-
and E-pockets. We propose that the altered positioning of
these side chains also may interfere with receptor binding,
either directly or indirectly by changing the overall confor-
mation of the peptide in the HLA-E groove.
The second important question concerns the biological
relevance of HLA-E/hsp60sp complexes. Our evidence
suggests that the increase of HLA-E levels observed during
stress results from an influx of hsp60-derived peptides into
the HLA-E presentation pathway. To critically investigate
this, we cotransfected K562 cells with HLA-E*01033 and
the full-length hsp60 signal sequence coupled to GFP
(hsp60L–GFP). This resulted in mitochondrial expression
of GFP, while HLA-E was expressed at high levels intracel-
lularly but only at low levels at the cell surface. As pre-
dicted from the model, the cell surface HLA-E levels were
increased in such cells when they were subjected to culture
induced stress, as compared with controls transfected with
HLA-E*01033 and a mutated hsp60L–GFP construct
where a critical HLA-E anchor residue had been substi-
tuted. Furthermore, our model predicted an up-regulation
of HLA-E also as a consequence of higher levels and altered
distribution of endogenous hsp60sp during stress. In line
with this, K562 cells transfected with HLA-E*01033 alone
also displayed increased levels of cell surface HLA-E upon
stress. Moreover, the up-regulation of HLA-E at the cell
surface, as a result of stress, did not protect from NK cell–
mediated killing in any of these experiments, as predicted.
It should however be possible to regain HLA-E–mediated
protection by adding a protective peptide, e.g. the B7sp
peptide. Indeed, we could protect the stressed cells, simply
by adding the protective B7sp peptide in the assay. This in-
dicates, but does not prove, that endogenous hsp60sp can
be presented by HLA-E during stress. Therefore, it remains
to be formally proven that HLA-E is important as a pre-
senter of stress-induced peptides for NK cells and T cells
during infection and inflammation. The elution and se-
quencing of peptides from isolated HLA-E molecules of
cells growing under normal conditions and cells exposed to
various stress stimuli would be required to assess whether
hsp60sp is indeed predominantly presented by stressed cells.
Our results further indicate that at least a part of the
stress-induced increased accessibility of hsp60sp to HLA-E
must be due to posttranscriptional factors. Such factors
could involve changes in protease activities, a more effi-
cient peptide transport from mitochondria to the ER, an
altered distribution of hsp60, or changes in the permeability
of the mitochondrial membrane. A majority (80–90%) of
the hsp60 pool is localized in the mitochondrial matrix in
healthy cells (35). There are, however, reports on increased
levels of extra-mitochondrial hsp60 after bacterial infection
(32) as well as after cellular stress and proapoptotic events
(33, 34). These observations have been made with the ma-
ture hsp60, but at least the effects on mitochondrial perme-
ability would also apply to the cleaved signal peptide.
In addition to altered mechanisms of peptide loading and
increased expression of hsp60sp, other peptides capable of
binding HLA-E may be up-regulated during stress. 10 yr1412 Stress-induced Peptides Interfere with CD94/NKG2A Recognition of HLA-E
ago, Imani and Soloski reported that a brief heat treatment
of L-cells increased the cell surface levels of Qa-1b (36). Lo
and coworkers recently reported that an hsp60-derived
peptide (GMQFDRGYL in Salmonella, and GMK-
FDRGYI in mouse) binds to Qa-1b (21). In addition, we
have confirmed that the peptide GMKFDRGYI (hsp60.4
in Table I) also can bind to HLA-E (unpublished data). In
contrast to the hsp60sp, this peptide could not compete
with the B7sp for binding to HLA-E (Fig. 6 d), nor could
it compete for binding to Qa-1b (37). It has also been dem-
onstrated that Qa-1b presenting hsp60.4 fail to protect the
cells from NK cell–mediated lysis (37). These ligands are
thus incapable of engaging CD94/NKG2A receptors, but
can instead be detected by clonotypic T cell receptors dur-
ing Salmonella infection in mice (21). It is therefore likely
that also other hsp60-derived peptides may become HLA-E
accessible during cellular stress provoked by an intracellular
infection. Hypothetically, these peptides would divert the
functional role of the HLA-E molecules as ligands for
CD94/NKG2 receptors toward complexes being able to be
recognized by certain T cells via their antigen-specific
TCR during an infection.
It should be noted that T cells can also express CD94/
NKG2A inhibitory receptors, and the balance between
HLA-E molecules with hsp60sp and MHC class I signal
peptide may therefore also modulate T cells in inflamma-
tory responses. In this context our present findings provide
an interesting extension to the recently published observa-
tions by Moser et al. (46), demonstrating that effector cyto-
toxic T lymphocytes directed against viral antigens may be-
come restrained through expression of CD94/NKG2A.
Recognition of Qa-1b via this receptor inhibited prolifera-
tion and effector function of the T cells, with a dramatic
influence on acute infection as well as oncogenesis by poly-
oma virus. The authors speculated that the peptide loading
of Qa-1b could be affected under pathological conditions,
possibly influencing the interaction with restrained T cells.
Our results demonstrate the loading of HLA-E with a pep-
tide that is not only induced in stressed cells, but also inter-
feres with the protection against CD94/NKG2A  NK cells
normally conferred by HLA-E. This provides a potential
explanation for the role of CD94/NKG2A expression dur-
ing the regulation of T cells responses. The coexpression of
this receptor would complement the TCR pathway in the
discrimination between healthy and sick cells not only by
sensing reduced production of MHC class I molecules but
also increased accessibility to HLA-E of stress-induced pep-
tides. Further studies to address this issue should test
whether CD94/NKG2 expressing human T cells can be
influenced by stressed induced changes in target cells. So
far, and as expected, analysis of peripheral blood from
healthy donors verified that the subset of CD94/NKG2A 
T cells also binds to HLA-E/B7sp tetramers. Furthermore
we have been unable to detect binding of HLA-E/hsp60sp
tetramers to either CD94/NKG2A  or CD94/NKG2A 
T cells (unpublished data), suggesting that T cells discrimi-
nate between different HLA-E complexes in the same way
as NK cells, and that T cells expressing a TCR specific for
HLA-E/hsp60sp are not abundant in healthy individuals.
HLA-E molecules are recognized by CD94/NKG2A in-
hibitory and CD94/NKG2C activating complexes. The
role of the activating forms has not yet been clearly de-
fined. The possibility that HLA-E/hsp60sp complexes are
recognized by CD94/NKG2C or another, unknown acti-
vating NK receptor is appealing. This could explain why
stressed K562-E*01033 cells were killed more efficiently by
NK cells, despite the increased HLA-E levels. However,
the NKL cell line does not express the activating NKG2C
receptor (unpublished data), and HLA-E/hsp60sp tetramers
did not bind to CD94/NKG2C transfectants, nor to any
NK cells examined. Thus, other ligands that trigger NK
cell activating receptors may be involved. Our data show
that neither MIC-A, or MIC-B, ligands for NKG2D, are
up-regulated on culture stressed K562 or K562-E*01033
cells. However, additional ligands for NKG2D (e.g.,
ULBPs [38]), or other activating receptors, may influence
the sensitivity of K562 and K562-E*01033 cells. Further
experiments using reagents that specifically block activating
NK cell receptors, may help to clarify the mechanism be-
hind the increased NK cell sensitivity upon culture stress.
NK cells can be divided in two major subsets based on
the level of CD56 cell surface expression (CD56dim and
CD56bright; reference 47). Cells belonging to the minor
CD56bright subset all express high levels of CD94/NKG2A,
and only a small fraction express KIRs. In contrast, a large
majority of the CD56dim NK cells express KIRs and display
a lower cell surface level of CD94/NKG2A (48), although
there are CD94/NKG2A , KIR  cells also in the CD56dim
subset. The phenotypical division between CD56dim and
CD56bright NK cells is associated with different effector
functions (49). When stimulated, CD56bright NK cells are
less cytototoxic, and more prone to cytokine production
and have therefore been proposed to be immunoregulatory
(49). These cells are potentially responsive to pro-inflam-
matory signals (based on their expression profile of chemo-
kine receptors and adhesion molecules), and are largely
over-represented at sites of inflammation (unpublished
data). Moreover, macrophages have been reported to re-
spond to human hsp60 with increased production of IL-12
and IL-15 (50), which are important activators of this NK
cell subset. The findings presented here, and the fact that
hsp60 is up-regulated during inflammation, suggest that
HLA-E–mediated presentation of hsp60sp would primarily
have an effect on CD94/NKG2A , KIR  NK cells in
both major NK cell subsets described above, and in partic-
ular on cytokine production by the CD56bright NK cells.
In summary, HLA-E could gradually change its peptide
repertoire from NK cell protective to nonprotective com-
plexes during infections and inflammatory responses. Such
a mechanism could be important to decrease the threshold
for NK cell activation during an immune response against
infections, without necessarily involving a specific patho-
gen-induced cellular change. Thus, HLA-E plays a dual
role as a marker for cellular health and integrity.1413 Michaëlsson et al.
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